Abzena (AIM:ABZA) is a UK life sciences group offering a range of services and technologies that enable its customers to develop safer and more effective biopharmaceutical products. Its core business is in its R&D service areas, which include immunology, protein engineering, ADC bioconjugation, synthetic chemistry and biomanufacturing.
In this video interview, CEO Dr John Burt discusses Abzena’s integrated business model and how its services and approach distinguish it from other companies in the biopharmaceutical space. He also details how it is establishing itself in the US following its two acquisitions in 2015. He gives an update on the second part of its business model, Abzena inside products, and highlights the risk-free upside this could provide. John concludes by talking about Abzena’s outlook for the next 24 to 36 months and the opportunities he sees for its future growth.